Michael Higgins
Stock Analyst at Ladenburg Thalmann
(1.79)
# 3,141
Out of 4,876 analysts
21
Total ratings
29.41%
Success rate
5.55%
Average return
Main Sectors:
Stocks Rated by Michael Higgins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Downgrades: Neutral | n/a | $14.62 | - | 4 | May 9, 2024 | |
| FBRX Forte Biosciences | Upgrades: Buy | $69 | $12.60 | +445.63% | 3 | Apr 8, 2024 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $7 | $0.34 | +1,961.25% | 1 | May 2, 2023 | |
| SCYX SCYNEXIS | Reiterates: Buy | $15 | $0.73 | +1,949.18% | 1 | Apr 3, 2023 | |
| ARTL Artelo Biosciences | Reiterates: Buy | $360 | $7.18 | +4,916.23% | 2 | Apr 3, 2023 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $35 | $61.22 | -42.83% | 3 | Mar 2, 2023 | |
| PHGE BiomX | Maintains: Buy | $130 → $80 | $0.45 | +17,764.60% | 2 | May 12, 2022 | |
| NVAX Novavax | Downgrades: Sell | $105 | $6.47 | +1,522.87% | 2 | Aug 5, 2020 | |
| VIRT Virtu Financial | Upgrades: Buy | $29 | $44.49 | -34.82% | 2 | Jan 4, 2019 | |
| SVRA Savara | Reinstates: Buy | n/a | $2.17 | - | 1 | Sep 27, 2017 |
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $14.62
Upside: -
Forte Biosciences
Apr 8, 2024
Upgrades: Buy
Price Target: $69
Current: $12.60
Upside: +445.63%
Ovid Therapeutics
May 2, 2023
Reiterates: Buy
Price Target: $7
Current: $0.34
Upside: +1,961.25%
SCYNEXIS
Apr 3, 2023
Reiterates: Buy
Price Target: $15
Current: $0.73
Upside: +1,949.18%
Artelo Biosciences
Apr 3, 2023
Reiterates: Buy
Price Target: $360
Current: $7.18
Upside: +4,916.23%
Rhythm Pharmaceuticals
Mar 2, 2023
Reiterates: Buy
Price Target: $35
Current: $61.22
Upside: -42.83%
BiomX
May 12, 2022
Maintains: Buy
Price Target: $130 → $80
Current: $0.45
Upside: +17,764.60%
Novavax
Aug 5, 2020
Downgrades: Sell
Price Target: $105
Current: $6.47
Upside: +1,522.87%
Virtu Financial
Jan 4, 2019
Upgrades: Buy
Price Target: $29
Current: $44.49
Upside: -34.82%
Savara
Sep 27, 2017
Reinstates: Buy
Price Target: n/a
Current: $2.17
Upside: -